Arthneeti
BA

Balaji Amines Ltd

Q1 FY25Chemicals & Petrochemicals

Balaji Amines Ltd Q1 FY25 Results & Presentation Highlights: Revenue ₹393 Cr, PAT ₹46 Cr

Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹2,226
Market cap₹7.0K Cr
P/E34.5
Updated25 Sept 2026
Read5 min read

Based on Balaji Amines Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q1FY25 consolidated revenue from operations: ₹393 crore, down 16% YoY from ₹469 crore in Q1FY24 (Page 5 & 6). Q1FY25 Consolidated EBITDA: ₹74 crore, down 29% YoY from ₹104 crore in Q1FY24 (Page 6, 10) - Q1FY25 Consolidated EBITDA Margin: 19%, down from 22% in Q1FY24 (Page 6, 10) - Q1FY25 Consolidated Profit After Tax (PAT): ₹46 crore, down 32% YoY from ₹68 crore in Q1FY24 (Page 5, 6, 10) - Q1FY25 PAT Margin: 12%, down from 16% in Q1FY24 (Page 6, 10) - Standalone EBITDA for Q1FY25: ₹64 crore, down 15% YoY from ₹56 crore in Q1FY24 (Page 5) - Standalone PAT for Q1FY25: ₹41 crore, up 19% YoY from ₹34 crore in Q1FY24 (Page 5) - No explicit forward-looking margin outlook is stated in the presentation.

From Balaji Amines Ltd's Q1 FY25 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q1FY25 consolidated revenue from operations: ₹393 crore, down 16% YoY from ₹469 crore in Q1FY24 (Page 5 & 6).
  • Total volumes in Q1FY25: 28,071 MT, slightly up from 27,984 MT in Q4FY24 (Page 6).
  • Volume breakdown Q1FY25: Amines – 7,401 MT; Amines Derivatives – 8,299 MT; Specialty Chemicals – 12,371 MT (Page 6).
  • Q1FY25 standalone revenue: ₹338 crore, down 1% YoY (Page 5).
  • No explicit quantitative revenue or volume growth outlook stated.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Unit 4 Greenfield Project (90-acre MIDC Chincholi):
  • Phase 2 & 3 Capex:
  • n-Butylamine plant (15,000 TPA) — Executed on schedule.
  • Methylamines plant (40,000 TPA) — Environmental clearance received; commissioning expected by Q3 FY25.
  • Dimethyl Ether (DME) plant (100,000 TPA) — Under execution; expected commissioning Q4 FY25.
  • Phase 1: Ethylamines plant operational since May 2021.
  • Other plants in progress: N-Methyl Morpholine (5000 TPA), N-(n-butyl) Thiophosphoric triamide (2500 TPA).
  • Capex to be completed by FY26.
  • Increased capacity utilization in Phase 1 plants.
  • Subsidiary Plant (Balaji Speciality Chemicals Limited):
  • New capex approx. Rs. 750 crores for speciality chemicals manufacturing.
  • Mega Project status granted by Maharashtra Govt.
  • Environmental clearance received; works ongoing.
  • Solar Power Plant:
  • 20 MW Greenfield Solar Power Plant near Solapur.
  • Phase 1 (8 MW) expected operational by Q4 FY25.

2 more points management made on capital expenditure plans

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem Ltd
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report or mention details about order book, order inflow, or pending orders. It focuses mainly on: - Financial performance and results highlights (revenue, EBITDA, PAT). - Growth prospects including new product development and capacity expansions. - ESG & CSR initiatives. - Greenfield solar power project and hotel expansion plans.

2 more points management made on order book & pipeline

Balaji Amines Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Balaji Amines Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Himadri Speciality Chemical Ltd (Q1 FY25)

    1,199.77 Cr, up 26.17% YoY (vs Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q1 FY25 investor presentation — and how it ranks a

  • Linde India Ltd (Q1 FY25)

    Revenue for year ended Mar 2024: ₹27,687 million, down 12% vs. Key investor presentation takeaways from Linde India Ltd's Q1 FY25 investor presentation — and ho

  • Vidhi Specialty Food Ingredients Ltd (Q1 FY25)

    83.0 Crs, up 4.1% year-on-year from Rs. Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY25 investor presentation — and how

  • GOCL Corporation Ltd (Q1 FY25)

    Consolidated revenue for FY 2023-24: INR 949 crores, down from INR 1409.71 crores in FY 2022-23. Key investor presentation takeaways from GOCL Corporation Ltd's

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Balaji Amines Ltd Q1 FY25 results?

Q1FY25 consolidated revenue from operations: ₹393 crore, down 16% YoY from ₹469 crore in Q1FY24 (Page 5 & 6). Q1FY25 Consolidated EBITDA: ₹74 crore, down 29% YoY from ₹104 crore in Q1FY24 (Page 6, 10) - Q1FY25 Consolidated EBITDA Margin: 19%, down from 22% in Q1FY24 (Page 6, 10) - Q1FY25 Consolidated Profit After Tax (PAT): ₹46 crore, down 32% YoY from ₹68 crore in Q1FY24 (Page 5, 6, 10) - Q1FY25 PAT Margin: 12%, down from 16% in Q1FY24 (Page 6, 10) - Standalone EBITDA for Q1FY25: ₹64 crore, down 15% YoY from ₹56 crore in Q1FY24 (Page 5) - Standalone PAT for Q1FY25: ₹41 crore, up 19% YoY from ₹34 crore in Q1FY24 (Page 5) - No explicit forward-looking margin outlook is stated in the presentation.

What is Balaji Amines Ltd share price analysis?

Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.

Is Balaji Amines Ltd planning capital expenditure?

Unit 4 Greenfield Project (90-acre MIDC Chincholi): - Phase 2 & 3 Capex: - n-Butylamine plant (15,000 TPA) — Executed on schedule. - Methylamines plant (40,000 TPA) — Environmental clearance received; commissioning expected by Q3 FY25. - Dimethyl Ether (DME) plant (100,000 TPA) — Under execution; expected commissioning Q4 FY25. - Phase 1: Ethylamines plant operational since May 2021. - Other plants in progress: N-Methyl Morpholine (5000 TPA), N-(n-butyl) Thiophosphoric triamide (2500 TPA). - Capex to be completed by FY26. - Increased capacity utilization in Phase 1 plants. - Subsidiary Plant (Balaji Speciality Chemicals Limited): - New capex approx.

Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.